SMC Signs Technology Transfer Agreement with Medinno for Stem-cell Therapy of Neonatal Brain Diseases
Samsung Medical Center (SMC) signed a technology transfer agreement on May 8 with CEO Joo, Kyung-min of Medinno Co., Ltd. on the development of stem-cell therapy for hypoxic ischemic encephalopathy (HIE), a neonatal intractable brain disease, and preterm severe intraventricular hemorrhage (IVH).
HIE and IVH are life threatening neonatal refractory brain diseases that cause cerebrovascular dysfunction, which requires lifetime rehabilitation in survived patients. Although there has been no effective treatment for the two diseases, stem-cell therapy has been proposed as a new alternative.
A research team led by Professor Chang Yun Sil of the SMC Department of Pediatrics developed the next generation stem-cell therapy technology with improved effects of the conventional mesenchymal stem cells for treatment of neonatal HIE. The team recently completed the preclinical test and received an approval for clinical test the Ministry of Food and Drug Safety. In addition, a collaborative research team led by Professor Park Won Soon and Professor Chang Yun Sil has been conducting clinical trials of mesenchymal stem-cell therapy for extremely preterm IVH for the first time in the world. The technology transfer agreement led the stem-cell therapy translational study on neonatal intractable brain diseases to preclinical to clinical trials.
Professor Im, Young Hyuck, vice president of research department, said: "The technology transfer agreement will lead to the development of stem-cell therapies, and we have come a step closer to the goal of neonatal intractable brain disease treatment."